Targets 2030: Operating profit greater than 30%; Adjusted EBITDA growing; FCF greater than $3.5B; Net leverage less than 2x.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva targets low-single digit revenue growth for FY27
- Teva says well-positioned to achieve 2030 financial targets
- Teva says ‘exciting growth’ emerging from biosimilar portfolio
- Teva sees FY26 adjusted EPS $2.57-$2.77, consensus $2.77
- Teva ‘continues to execute’ on pillars of ‘Pivot to Growth’ strategy